OsteoBiologics and US Biomaterials pool technologies
This article was originally published in Clinica
Bioactive materials for reconstructive surgery and dentistry are the object of a licence agreement between US companies OsteoBiologics and US Biomaterials. By pooling USB's Bioglass technology and OBI's Immix scaffolds, the companies plan to develop products which will promote bone and cartilage repair following reconstructive surgery.
You may also be interested in...
Updated data from a postmarket study of Abiomed’s Impella RP right-heart pump further supports the device’s safety for a specific patient population.
The new US-Mexico-Canada (USMCA) trade agreement includes language on enhancing regulatory compatibility between the three countries by recognizing quality systems audits performed under the Medical Device Single Audit Program (MDSAP). It also stipulates that each trading partner “consider its resources and technical capacity” in ensuring the safety, effectiveness and quality of devices – and more. Medtech industry advocacy group AdvaMed is praising the deal, reached by the three countries on 10 December.
Novo Nordisk’s CEO talks to Scrip about the promise of glucose-responsive insulin, stem cell therapy, and a diabetes landscape without Sanofi.